Recombinant Human ALG13 293 Cell Lysate
Cat.No. : | ALG13-8908HCL |
- Specification
- Gene Information
- Related Products
- Download
Description : | Antigen standard for asparagine-linked glycosylation 13 homolog (S. cerevisiae) (ALG13), transcript variant 2 is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection. |
Source : | HEK 293 cells |
Species : | Human |
Components : | This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol). |
Size : | 0.1 mg |
Storage Instruction : | Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment. |
Applications : | ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane. |
Gene Name : | ALG13 asparagine-linked glycosylation 13 homolog (S. cerevisiae) [ Homo sapiens ] |
Official Symbol : | ALG13 |
Synonyms : | ALG13; asparagine-linked glycosylation 13 homolog (S. cerevisiae); chromosome X open reading frame 45 , CXorf45, GLT28D1, glycosyltransferase 28 domain containing 1; UDP-N-acetylglucosamine transferase subunit ALG13 homolog; FLJ23018; MDS031; YGL047W; glycosyltransferase 28 domain-containing protein 1; hematopoietic stem/progenitor cells protein MDS031; CXorf45; GLT28D1; FLJ31785; MGC12423; |
Gene ID : | 79868 |
mRNA Refseq : | NM_001039210 |
Protein Refseq : | NP_001034299 |
MIM : | 300776 |
UniProt ID : | Q9NP73 |
Chromosome Location : | Xq23 |
Pathway : | Asparagine N-linked glycosylation, organism-specific biosystem; Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein, organism-specific biosystem; Metabolic pathways, organism-specific biosystem; Metabolism of proteins, organism-specific biosystem; N-Glycan biosynthesis, organism-specific biosystem; N-Glycan biosynthesis, conserved biosystem; N-glycan precursor biosynthesis, organism-specific biosystem; |
Function : | N-acetylglucosaminyldiphosphodolichol N-acetylglucosaminyltransferase activity; carbohydrate binding; transferase activity, transferring hexosyl groups; |
Products Types
◆ Recombinant Protein | ||
ALG13-464M | Recombinant Mouse ALG13 Protein, His (Fc)-Avi-tagged | +Inquiry |
ALG13-0610H | Recombinant Human ALG13 Protein (S221-D372), Tag Free | +Inquiry |
ALG13-0611H | Recombinant Human ALG13 Protein (S221-D372), His tagged | +Inquiry |
ALG13-284R | Recombinant Rat ALG13 Protein, His (Fc)-Avi-tagged | +Inquiry |
ALG13-1544M | Recombinant Mouse ALG13 Protein | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (19)
Ask a questionThe protein encoded by the ALG13 gene catalyzes its receptor in an acylated manner, making it a substrate for glycosyltransferase, thereby transmitting its catalytic activity.
The mutations have been linked to neurological disorders such as idiopathic epilepsy and intellectual disability.
Appropriate genetic analysis methods, including single genotypic/association analysis and genome-linked DNA polymorphism analysis, can be used to assess the genetic risk of ALG13 gene variation and neurological diseases.
At present, there are not enough studies to prove that ALG13 mutations are directly related to diseases such as cardiovascular disease and metabolic syndrome.
ALG13 is a member of the UDP-glucose-glycosyltransferase family, which is mainly involved in protein glycosylation.
The ALG13 gene has not been linked to the evolutionary history of humans.
This mutations may affect neuronal development and nerve conduction processes, leading to a range of neurological diseases.
CRISPR/Cas9 gene editing technology can be used to construct ALG13 gene knockout or mutant cell lines, and its effects on cell growth and glycosylation process can be analyzed through comparative experiments.
No studies have directly linked ALG13 with AMPK and mTOR, and further research is needed.
The potential role of ALG13 in the early prediction and treatment of diabetes has not been studied, which requires further research.
In this study, we can use gene editing technology to construct ALG13 gene knockout or mutant cell lines, and then compare the differences in glucose metabolism and energy metabolism between them and wild-type cells.
There is currently no direct evidence of a correlation between ALG13 and metabolism and obesity.
At present, there is no conclusive evidence that ALG13 has a direct regulatory effect on glucose levels and energy metabolism, but genomic studies suggest that it may be involved in the mechanisms of glucose metabolism pathways.
ALG13 encodes an important glycosyltransferase, and its mutation can affect the glycosylation process of proteins, and thus affect the efficiency and quality of glycosylation.
Glycosylation is one of the important ways of protein modification, and the glycosylation of ALG13 can affect the folding, activity and stability of the protein, so as to affect the function of the protein.
The enzyme activity of ALG13 is controlled by various regulatory mechanisms. One is to interact with the sugar chain component glycosyl budding to regulate its activity and stability; The other is its own acylation modification, which affects the activity.
ALG13 is involved in metastasis as glycosylation and affects neuronal papillary process signaling, etc. Further studies are needed to understand its unique mechanism.
The relationship between ALG13 gene polymorphism and other genetic or environmental factors is limited and further research is needed.
The amount and pattern of ALG13 expression in different tissues are different, such as high expression in brain, lung and kidney.
Customer Reviews (3)
Write a reviewStrong antioxidant effect, can inhibit the formation of free radicals, reduce oxidation reaction.
The clinical detection method is mature.
Great performance in ELISA.
Ask a Question for All ALG13 Products
Required fields are marked with *
My Review for All ALG13 Products
Required fields are marked with *
Inquiry Basket